<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02187367</url>
  </required_header>
  <id_info>
    <org_study_id>BV-NSCLC-002</org_study_id>
    <secondary_id>2013-005335-25</secondary_id>
    <nct_id>NCT02187367</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients</brief_title>
  <acronym>EGF</acronym>
  <official_title>Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety &amp; Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioven Europe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioven Sdn. Bhd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The vaccine contains humanized recombinant antigen (EGF - Epithelial Growth Factor) and an
      adjuvant. The antibodies induced by vaccination will react with circulating EGF leading to
      removal of EGF from the circulation. As a result, binding to its target EGF-Receptor is
      prevented. Blocking of EGF-Receptor is preventing activation and stimulation of proliferation
      of tumour cell. A Phase 3 clinical trial on the EGF vaccine is ongoing in Cuba. The result
      from previous studies demonstrated positive correlation between extended survival and immune
      response against the vaccination in the late-stage NSCLC patients' age below 60 with improved
      quality of life. The purpose of this international Phase 3 trial is to determine whether the
      recombinant human EGF cancer vaccine is safe, immunogenic and effective in the treatment of
      stage IV NSCLC patients who are positive in the selective EGF biomarker and wild type
      EGF-Receptor compared to standard treatment and supportive care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Each patient will be followed till death occurs within study time frame of 3 years</time_frame>
    <description>To assess overall survival (OS) of an EGF cancer vaccine in inoperable, stage IV biomarker positive, wild type EGF-R, NSCLC patients compared to the control group receiving best treatment and supportive care. OS is defined as the time from randomisation to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of EGF Cancer Vaccine as assessed by Adverse Events (AEs)</measure>
    <time_frame>Each patient will be followed till death occurs within study time frame of 3 years</time_frame>
    <description>To assess the frequency and number of patients develop AEs, related AEs, serious AEs (SAEs) and AEs leading to withdrawal or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Each patient will be followed till objective tumour progression or death (whichever occurs first) within time frame of study of 3 years</time_frame>
    <description>Progression parameters include radiological or clinical progression, withdrawal due to progression, and death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Rate</measure>
    <time_frame>Each patient will be followed at 12 and 24 months after randomization</time_frame>
    <description>To assess the percentage of patients that are alive at 12 months and 24 months in EGF cancer vaccine study group compared to control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Each patient will be followed till observed tumour progression within study time frame of 3 years</time_frame>
    <description>To assess Time to Progression (TTP) from the time of randomisation to first documented disease progression of EGF cancer vaccine study group patients compared to control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RECIST criteria)</measure>
    <time_frame>Each patients will be followed till death occurs within study time frame of 3 years</time_frame>
    <description>To assess the percentage of patients with a complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria Version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of EGF Cancer Vaccine by Laboratory Assessment</measure>
    <time_frame>Each patients will be followed till death occurs within study time frame of 3 years</time_frame>
    <description>To assess haematology, biochemistry and urinalysis parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of EGF Cancer Vaccine assessed by Vital Signs</measure>
    <time_frame>Each patients will be followed till death occurs within study time frame of 3 years</time_frame>
    <description>To assess systolic and diastolic blood pressure, body temperature and pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of EGF Cancer Vaccine as assessed by Physical Examination</measure>
    <time_frame>Each patient will be followed till death occurs within study time frame of 3 years</time_frame>
    <description>To assess eyes, neurological and cardiovascular systems, lungs, abdomen, and any other areas with signs and symptoms of disease, and of the head, neck, ears, nose, mouth, throat, thyroid, lymph nodes and extremities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>Each patient will be followed till death occurs within study time frame of 3 years</time_frame>
    <description>To assess the general physical health of patients with a 36-item, short-form health survey until disease progression</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamics (PD) of EGF Cancer Vaccine assessed by Immune Responses</measure>
    <time_frame>Each patients will be followed till death within study time frame of 3 years</time_frame>
    <description>To assess the serum EGF concentration and anti-EGF antibody titers with response before and after to the study treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy assessed by KRAS and ALK rearrangements</measure>
    <time_frame>At time of screening</time_frame>
    <description>For the analysis of oncogenes Kirsten rat sarcoma (KRAS) and anaplastic lymphoma kinase (ALK), a formalin-fixed, paraffin embedded (FFPE) sample of the biopsy tumour tissue, ideally taken from biopsy obtained at disease diagnosis will be prepared and shipped for central analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">418</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>EGF Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive a low dose of cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Supportive Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will receive best supportive care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EGF Vaccine</intervention_name>
    <description>1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.</description>
    <arm_group_label>EGF Vaccine</arm_group_label>
    <other_name>Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Are aged 18 or older.

          2. Have serum EGF concentration &gt;250 pg/ml determined from sample taken at screening.

          3. Have wild type EGF-R sequence.

          4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          5. Have adequate bone marrow, liver and renal function, as assessed by the Investigator.
             A sample taken at Screening should confirm that:

               -  White blood cell (WBC) count ≥ 3000 per µL

               -  Platelet count ≥ 100,000 per µL

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper
                  limit of normal (ULN) (or ≤ 5 x ULN when liver metastases are present)

               -  Total bilirubin ≤ 1.5 x ULN

               -  Serum creatinine ≤ 1.5 x ULN

          6. Have histologically and/or cytologically confirmed diagnosis of NSCLC, corresponding
             to locally and regionally advanced inoperable disease (Stage IV [as defined by the
             American Joint Committee on Cancer staging system- TNM 7th edition 2010]) excluding
             brain metastases.

          7. Are eligible to receive first-line chemotherapy (without concurrent radiotherapy to
             thorax measurable lesions or consolidation radiotherapy).

          8. Agree to use double-barrier contraception (males and females alike [if applicable]). A
             negative pregnancy test must be documented at Screening for females of childbearing
             potential.

             Note: Females of childbearing potential are defined as those women with less than 2
             years after last menstruation and not surgically sterile, while post-menopausal refers
             to those women with at least 2 years from last menstruation.

          9. Have signed a voluntary written informed consent form (ICF). Patients should be
             cooperative, willing and able to participate and adhere to the Protocol requirements,
             including their availability for the follow-up.

        Exclusion Criteria:

          1. Patient has no measurable disease (as defined by RECIST Criteria, version 1.1).

          2. Patient has EGF-R mutation.

          3. Patient has EGF serum concentration below required threshold.

          4. Patient is a candidate for concurrent chemo-radiotherapy or post chemo thoracic
             radiotherapy.

          5. Patient has a history of known or suspected central nervous system (CNS) metastases.

          6. Patient has a history of primary malignancy (except resected non-melanoma skin cancer
             or curatively treated carcinoma in situ of the cervix), unless in complete remission
             and off all chemotherapy and/or radiotherapy for that disease for a minimum of 5
             years. Any palliative radiotherapy to alleviate pain in bone metastases is permitted.

          7. Patient is taking immunosuppressant drugs such as azathioprine, tacrolimus,
             cyclosporine, etc. Use is not permitted within 1 month before Screening.

          8. Patient is taking any other immunotherapy.

          9. Patient has primary or secondary immunodeficiencies (e.g. documented Human
             Immunodeficiency Virus [HIV]).

         10. Patient has autoimmune disease.

         11. Patient has undergone splenectomy.

         12. Patient is taking oral, intramuscular or intravenous corticosteroids. Use is not
             permitted within 1 month before Screening. Inhaled corticosteroids to treat
             respiratory insufficiency (e.g. chronic obstructive pulmonary disease [COPD]), or
             topical steroids are permitted.

         13. Patient has neurotoxicity (Grade ≥2).

         14. Patient has diarrhoea (Grade ≥2).

         15. Patient has received other vaccines (with the exception of the influenza vaccine),
             within 1 month before Screening.

         16. Patient has a history of any severe or life-threatening hypersensitivity reaction.

         17. Patient has an unstable systemic disease (including active infection, uncontrolled
             hypertension, unstable angina, congestive heart failure, myocardial infarction within
             the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal and
             metabolic disease).

         18. Patient has recent history (within 6 months before Screening) of chronic alcohol or
             drug abuse which may compromise the patient's safety or ability to participate in
             study activities.

         19. Patient has a history of psychiatric disorder that prevents patients from providing
             informed consent or following Protocol instructions.

         20. Patient is currently enrolled in an investigational device or drug trial, or &lt;1 month
             since completing an investigational device or drug trial.

         21. Female patients who are pregnant or lactating.

         22. Patient has any other factor that in the opinion of the Investigator (or designee)
             would make the patient unsafe or unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Nicolson, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aberdeen Royal Infirmary, Foresterhill, Aberdeen, AB25 2ZN, United Kingdom</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik D'hondt, Dr.</last_name>
    <email>erik@bioven.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nemocnice Na Pleši s.r.o. Oddelení klinické onkologie a radioterapie</name>
      <address>
        <city>Nová Ves pod Pleší</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Vydra, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pardubická krajská nemocnice, a.s.c</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaroslav Vaňásek, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Adjara</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Memed Jincharadze, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic Health House</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kakhaber Baramidze, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Oncology</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vladimer Kuchava, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC, Maritime Hospital</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teimuraz Gogitidze, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC, Neo Medi</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mikheil Shavdia, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LTD, High Technology Medical Centre, University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miranda Gogishvili, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LTD, Medulla - Chemotherapy and Immunotherapy Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tamta Makharadze, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute Of Clinical Medicine</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tamar Melkadze, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale) Klinik und Poliklinik fuer Innere Medizin</name>
      <address>
        <city>Halle</city>
        <state>Saale</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susanne Behl, Ms</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonas Engelbertz, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg gGmbH</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Liersch, Mr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein (UKSH)</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anja Ketelson, Ms.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig - AöR</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramona Röhrborn, Ms</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMU-München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rudolf-Maria Huber, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mühlen-Apotheke</name>
      <address>
        <city>Oststeinbek</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kerstin Harder, Ms</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Bahiyah</name>
      <address>
        <city>Alor Setar</city>
        <state>Kedah</state>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Razul Nazri, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jyi Lin Wong, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mahkota Medical Center</name>
      <address>
        <city>Malacca</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjeev Chandra Joshi, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>Pulau Pinang</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irfhan Ali, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital</name>
      <address>
        <city>Lahug</city>
        <state>Cebu City</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Tudtud, Mr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati</city>
        <state>Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Belen Tamayo, Ms</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Medical City</name>
      <address>
        <city>Pasig</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Tiangco, Ms</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lung Center of the Philippines</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sullian Naval, Mr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Davao Doctors hospital</name>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felycette Lapus, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnold Germar, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priscilla Caguioa, Ms.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosa Maria Alvarez, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jimenez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Dómine, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Mariano Provencio, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vanesa Gutiérrez, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lopburi Cancer Hospital</name>
      <address>
        <city>Mueang</city>
        <state>Lopburi</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piti Pornprasertsuk, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arunee Dechaphunkul, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bangkok Hospital Chiang Mai</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sumitra Thongprasert, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lampang Cancer Hospital</name>
      <address>
        <city>Lampang</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sirikul Sorraritchingchai, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Buddhachinaraj Hospital</name>
      <address>
        <city>Phitsanulok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manoch Buranachokphaisan, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allan Price, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Nicolson, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barking, Havering and Redbridge University Hospitals NHS Trust</name>
      <address>
        <city>Essex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathryn Tarver, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivo Hennig, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Ottensmeier, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2014</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

